PGT-A

Quick takeaways

• PGT-A is a chromosome screening test used on IVF embryos before transfer.
• It looks for aneuploidy, meaning an abnormal number of chromosomes.
• A euploid embryo has the expected chromosome count; an aneuploid embryo does not.
• PGT-A may help with embryo selection, but it does not guarantee implantation, pregnancy, or live birth.
• Results can include mosaic findings, which can be more complex to interpret.
• PGT-A is different from testing for single-gene diseases or structural chromosome rearrangements.
• Male-factor infertility can influence IVF planning, but sperm issues do not automatically mean PGT-A is necessary.
• Deciding whether to use PGT-A should involve a fertility specialist and, ideally, a genetic counselor.

What does PGT-A mean?

PGT-A is the current term for what was previously often called PGS, or preimplantation genetic screening. The shift in terminology matters: “screening” more accurately reflects what the test does. PGT-A estimates whether the sampled embryo cells appear to have a normal or abnormal chromosome number. It is not the same as a full diagnostic genetic workup.

Humans typically have 46 chromosomes, arranged in 23 pairs. If an embryo has extra or missing chromosomes, that pattern is called aneuploidy. Many aneuploid embryos do not implant, and some implant but end in miscarriage. A smaller number can result in chromosomal conditions such as trisomy 21.

Because chromosome errors become more common as eggs age, PGT-A is often discussed in the setting of maternal age. Still, it is relevant to both partners because embryo creation, fertilization strategy, sperm quality, and IVF outcomes are shared parts of the fertility picture.

How PGT-A works during IVF

PGT-A is done as part of an IVF cycle, not as a standalone fertility test. The basic process usually looks like this:

1. Ovarian stimulation to produce multiple eggs.
2. Egg retrieval in the fertility clinic.
3. Fertilization with sperm, often by conventional insemination or ICSI.
4. Embryo culture in the lab until the blastocyst stage, typically day 5, 6, or sometimes day 7.
5. Embryo biopsy, where a few cells are removed from the trophectoderm, the part that later contributes to the placenta rather than the fetus itself.
6. Freezing of the embryo while testing is completed.
7. Genetic analysis of the biopsied cells using techniques such as next-generation sequencing.
8. Embryo transfer planning based on PGT-A results and the broader clinical picture.

What exactly is being tested?

The lab analyzes the DNA from the sampled cells to estimate whether each chromosome is present in the expected amount. It does not measure embryo “health” in a broad sense. It also does not tell you whether the embryo has every possible disease, developmental issue, or future medical problem.

Does the biopsy harm the embryo?

Modern blastocyst biopsy techniques are widely used, but no procedure is completely risk-free. Skilled embryology labs aim to minimize harm, and many clinics routinely freeze biopsied embryos successfully. Even so, outcomes depend on embryo quality, lab expertise, clinic protocols, and individual circumstances.

Who might consider PGT-A?

PGT-A is not automatically recommended for everyone doing IVF. Whether it is helpful depends on age, embryo numbers, history, and the goals of treatment.

People who may discuss PGT-A with their fertility team include:

• Women of advanced maternal age
• Couples with recurrent miscarriage
• Patients with repeated failed embryo transfers
• Those who have produced multiple blastocysts and want help selecting one for transfer
• Couples using donor eggs or donor sperm in specific clinical scenarios
• Patients with a prior pregnancy or embryo affected by a chromosome number abnormality

Situations where the benefit may be less clear

If only a small number of embryos are expected, or if very few reach blastocyst, the value of PGT-A may be more debatable. In some cases, the biopsy and testing process can leave no transferable embryo if all tested embryos are reported abnormal or if there are no embryos suitable for biopsy.

This is why individualized counseling matters. The right decision depends on the chance of creating multiple embryos, age-related aneuploidy risk, prior IVF history, and how comfortable you are with uncertainty.

How to read PGT-A results

PGT-A results are often grouped into a few broad categories. Exact wording varies by lab.

What does “euploid embryo” mean?

A euploid embryo is one whose tested cells have the expected number of chromosomes. This generally makes it more promising for transfer than an aneuploid embryo, but it is still not a guarantee of success. Implantation can still fail, and miscarriage can still happen for reasons unrelated to the chromosome count detected by PGT-A.

What does “aneuploid embryo” mean?

An aneuploid embryo has extra or missing chromosome material in the tested sample. Examples include monosomy or trisomy affecting one or more chromosomes. Many aneuploid embryos stop developing, do not implant, or miscarry early.

What does “mosaic embryo” mean?

A mosaic embryo has a mixed result in the sampled cells, suggesting that some cells may be euploid and others aneuploid. Mosaicism is one of the most debated areas in reproductive genetics because the biopsy samples only a small part of the embryo. Some mosaic embryos can still result in healthy live births, while others may not implant or may miscarry. Transfer decisions should be made with experienced clinical and genetic counseling input.

What’s normal vs what’s not?

Unlike a hormone level or semen analysis count, PGT-A does not have a “normal range.” Instead, results are interpreted by category.

Does a normal PGT-A result mean the embryo is healthy?

No. A euploid result means the tested cells appear to have the expected chromosome number. It does not rule out all genetic diseases, birth defects, developmental issues, or pregnancy complications. Prenatal testing in pregnancy may still be recommended even after transfer of a euploid embryo.

What does PGT-A mean in men’s health and fertility?

PGT-A is often framed as an embryo test rather than a men’s health topic, but it frequently comes up in male fertility care. Men and male partners may encounter PGT-A in the setting of:

• Male-factor infertility, such as low sperm count, poor motility, or abnormal morphology
• High sperm DNA fragmentation concerns
• Use of ICSI as part of IVF
• Prior failed IVF cycles where embryo selection becomes a major discussion point
• Questions about miscarriage risk and whether genetic screening is worthwhile

Does poor sperm quality cause abnormal PGT-A results?

The relationship is not simple. Aneuploidy risk is strongly influenced by egg quality and maternal age, but sperm factors can also affect embryo development and overall reproductive outcomes. Severe male-factor infertility, certain genetic abnormalities in the male partner, or high DNA fragmentation may be relevant in some cases, though they do not map neatly onto PGT-A categories.

Importantly, low semen parameters do not automatically mean embryos will be aneuploid, and normal semen parameters do not guarantee euploid embryos. Fertility is a shared system, and embryo genetics reflect contributions from both partners plus the biology of cell division after fertilization.

When male partners should ask deeper questions

If there is significant male-factor infertility, it may be worth asking whether additional evaluation is appropriate, such as:

• Semen analysis review
• Sperm DNA fragmentation testing in selected cases
• Male hormone testing
• Physical exam for varicocele or other treatable factors
• Karyotype or Y chromosome microdeletion testing if sperm counts are very low

These are separate from PGT-A, but they can influence the broader IVF strategy.

Benefits, limitations, and risks of PGT-A

Potential benefits

• May help select embryos with a better chance of implantation
• May reduce the chance of transferring an embryo with a major chromosome number abnormality
• May lower the risk of miscarriage related to aneuploidy in some patients
• Can support single embryo transfer decisions by giving more information about embryo selection
• May shorten time to pregnancy for some patients by reducing transfer of clearly aneuploid embryos

Important limitations

• It is a screening test, not a perfect diagnostic test.
• The biopsy samples only a few cells, not the entire embryo.
• Mosaic results may be difficult to interpret.
• A euploid result does not guarantee implantation, healthy pregnancy, or live birth.
• PGT-A does not detect every genetic disease.
• Testing adds cost, lab steps, and usually embryo freezing.

Possible downsides or risks

• Embryos may be categorized in ways that are not perfectly predictive
• Some potentially viable embryos, especially certain mosaic embryos, may be deprioritized or not transferred depending on clinic policy
• The biopsy procedure and freeze-thaw process introduce additional handling
• There may be emotional stress if all embryos are reported abnormal or inconclusive

Does PGT-A improve live birth rates?

This is where nuance matters. PGT-A may improve embryo selection and reduce transfer of aneuploid embryos, but whether it improves cumulative live birth rates for all patient groups remains an area of ongoing debate. In some groups, especially where many embryos are available, it may help with efficiency. In others, especially younger patients with fewer embryos, the benefit may be less clear.

PGT-A vs PGT-M vs PGT-SR

These terms are often confused, but they answer different genetic questions.

Why this distinction matters

A couple may be told they do not need PGT-A but do need PGT-M or PGT-SR, or vice versa. For example, if a man has a known balanced translocation on karyotype, PGT-SR may be especially relevant. If a family carries a known mutation for cystic fibrosis or another inherited condition, PGT-M may be the focus instead.

How PGT-A affects treatment decisions

PGT-A does not treat infertility directly. Instead, it provides information that may shape IVF decision-making.

Ways it can influence care

• Choosing which embryo to transfer first
• Deciding whether to transfer one embryo instead of more than one
• Planning around frozen embryo transfer
• Interpreting repeated failed transfers
• Guiding counseling after miscarriage history

If all embryos are aneuploid

This can be one of the hardest IVF outcomes emotionally and medically. It may lead to discussions about another IVF cycle, changing stimulation protocols, using donor eggs or donor sperm in specific cases, re-evaluating the male partner and female partner, or reviewing whether additional genetic testing is indicated.

If you have mosaic embryos only

Some clinics consider transfer of selected mosaic embryos when no euploid embryos are available, usually after detailed counseling about uncertainty, implantation potential, miscarriage risk, and prenatal follow-up. Policies vary widely by clinic and lab.

Can you improve PGT-A results naturally?

There is no proven “natural” method to directly change an embryo’s chromosome status once it exists. However, optimizing preconception health may support overall fertility and IVF outcomes. This includes:

• Avoiding tobacco, vaping, and recreational drugs
• Limiting excessive alcohol use
• Maintaining a healthy body weight when possible
• Addressing sleep, stress, and metabolic health
• Managing heat exposure and environmental exposures that may affect sperm quality
• Treating underlying male-factor issues when present
• Following evidence-based supplement or medication plans recommended by a fertility specialist

For men, improving semen quality and general reproductive health can still be worthwhile even though it does not guarantee euploid embryos.

Related tests and terms

• IVF – in vitro fertilization
• ICSI – intracytoplasmic sperm injection
• Blastocyst – embryo stage commonly biopsied for PGT-A
• Aneuploidy – abnormal chromosome number
• Euploid – expected chromosome number
• Mosaic embryo – mixed chromosomal cell lines in the tested sample
• Karyotype – chromosome analysis of a person’s cells
• PGT-M – testing for single-gene diseases
• PGT-SR – testing for structural chromosome rearrangements
• Prenatal testing – screening or diagnostic testing during pregnancy after embryo transfer

Questions to ask your doctor about PGT-A

If PGT-A is part of your IVF conversation, these questions can help:

1. Am I a good candidate for PGT-A based on my age, diagnosis, and expected embryo number?
2. What are the clinic’s live birth, implantation, and miscarriage outcomes with and without PGT-A in patients like me?
3. How does your lab define and report mosaic embryos?
4. What happens if an embryo result is inconclusive?
5. Will embryos be biopsied on day 5, day 6, or day 7, and does that affect transfer planning?
6. Does severe male-factor infertility change whether PGT-A is recommended in my case?
7. Should we meet with a genetic counselor before deciding?
8. If no euploid embryos are found, what are the next best options?
9. Do you still recommend prenatal testing if a euploid embryo results in pregnancy?

When to seek medical advice

You should speak with a fertility specialist or reproductive endocrinologist if:

• You are starting IVF and want to understand whether embryo testing makes sense
• You have had recurrent miscarriage or repeated failed transfers
• Your IVF cycle produced mosaic, aneuploid, or inconclusive embryo results
• You or your partner has a known genetic condition or chromosome rearrangement
• You are dealing with severe male-factor infertility and want a fuller fertility workup

A genetic counselor can be especially helpful if results are complex, emotionally difficult, or likely to influence major reproductive decisions.

Common myths and misconceptions about PGT-A

Myth: PGT-A guarantees a healthy baby

Reality: It does not. PGT-A screens for chromosome number abnormalities in sampled embryo cells. It cannot rule out all genetic, structural, developmental, or pregnancy-related problems.

Myth: A euploid embryo will always implant

Reality: Implantation depends on many factors, including embryo biology beyond chromosome count, the uterine environment, transfer technique, and chance.

Myth: PGT-A is only relevant to women

Reality: The test is performed on embryos, and embryo outcomes matter to both partners. Male infertility evaluation can still be highly relevant to IVF planning.

Myth: PGT-A detects every inherited disease

Reality: It does not. PGT-M is used for known single-gene disorders, and PGT-SR is used for structural chromosome rearrangements.

Myth: Mosaic embryos can never lead to a healthy birth

Reality: Some mosaic embryo transfers have resulted in healthy live births. Interpretation and decision-making are complex and should be individualized.

Frequently asked questions about PGT-A

Is PGT-A worth it?

It depends on the patient. PGT-A may be useful for some IVF patients, especially when there are multiple embryos to choose from or a history suggesting chromosome-related loss. For others, the added cost and complexity may not provide a clear advantage.

Does PGT-A improve IVF success rates?

It may improve embryo selection and reduce transfer of aneuploid embryos, but it does not guarantee success. Whether it improves cumulative live birth rates for a specific patient group remains an individualized question.

What is the difference between PGT-A and genetic testing during pregnancy?

PGT-A is done on embryos before transfer during IVF. Prenatal testing is done during pregnancy and may include screening or diagnostic tests such as NIPT, CVS, or amniocentesis.

Can PGT-A be wrong?

No test is perfect. Because only a small number of embryo cells are sampled, there can be uncertainty, especially with mosaic or inconclusive results. This is one reason prenatal testing is still discussed after pregnancy is achieved.

Does PGT-A test for Down syndrome?

PGT-A can identify chromosome number abnormalities consistent with trisomies, including trisomy 21, which is associated with Down syndrome. However, it remains a screening tool, not a final prenatal diagnosis.

How long does PGT-A take?

Timing varies by clinic and laboratory, but results are commonly available within days to a couple of weeks after biopsy. Because embryos are often frozen after biopsy, transfer usually happens in a later cycle.

What happens if no embryos are euploid?

Your care team may discuss another IVF cycle, review stimulation strategy, consider donor gametes in selected cases, re-evaluate fertility factors in both partners, or talk through whether any mosaic embryos are candidates for transfer.

Does PGT-A tell you the sex of the embryo?

Because it analyzes chromosomes, the test may identify sex chromosomes. Whether that information is shared or used depends on local laws, clinic policies, and ethical considerations.

Do you need PGT-A for male-factor infertility?

Not necessarily. Male-factor infertility may lead to IVF or ICSI, but PGT-A is a separate decision. The best choice depends on age, embryo numbers, prior outcomes, and the broader medical picture.

Bottom line

PGT-A is an IVF embryo screening test used to look for chromosome number abnormalities before transfer. It can be helpful in some fertility journeys, especially when embryo selection is a major concern, but it is not a universal must-have and not a guarantee of success. For men and couples navigating infertility, the smartest approach is individualized: understand what PGT-A can and cannot tell you, place it in the context of the full fertility workup, and make decisions with a fertility specialist and, when useful, a genetic counselor.

References

• American Society for Reproductive Medicine (ASRM). Committee opinions and practice guidance on preimplantation genetic testing and IVF.
• European Society of Human Reproduction and Embryology (ESHRE). Good practice recommendations for preimplantation genetic testing.
• American College of Obstetricians and Gynecologists (ACOG). Guidance on prenatal genetic screening and diagnostic testing.
• The Preimplantation Genetic Diagnosis International Society (PGDIS). Position statements on embryo biopsy, PGT-A, and mosaic embryo transfer.
• Centers for Disease Control and Prevention (CDC). Assisted reproductive technology resources and patient information.
• Peer-reviewed reproductive medicine literature on embryo aneuploidy, mosaicism, and IVF outcomes in journals such as Fertility and Sterility and Human Reproduction.